Vivosim Lab Inc (VIVS)

Apr 24, 2025, 8:05 AM EDT - 1 day ago

VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market

Apr 23, 2025, 8:05 AM EDT - 2 days ago

VivoSim to Carry Forward Organovo 3D Bioprinting

Apr 2, 2025, 8:05 AM EDT - 23 days ago

Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements

Mar 27, 2025, 8:05 AM EDT - 4 weeks ago

Organovo Provides Business Update

Mar 25, 2025, 11:25 AM EDT - 4 weeks ago

Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company

LLY

Mar 19, 2025, 8:05 AM EDT - 5 weeks ago

Organovo Announces Reverse Stock Split

Mar 11, 2025, 7:00 AM EDT - 6 weeks ago

Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

GRCE MTNB

Mar 6, 2025, 8:05 AM EST - 7 weeks ago

Organovo Announces the Issuance of Additional Shares in Conjunction with Warrant Exercises

Feb 25, 2025, 8:05 AM EST - 2 months ago

Organovo's FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company

Jan 6, 2025, 8:05 AM EST - 3 months ago

Organovo Announces Appointment of Norman Staskey as Chief Financial Officer

Nov 20, 2024, 8:05 AM EST - 5 months ago

Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting

Nov 13, 2024, 8:06 AM EST - 5 months ago

Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases

Jul 18, 2024, 7:55 AM EDT - 10 months ago

Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July

ASLN CERO

Jul 16, 2024, 8:05 AM EDT - 10 months ago

Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis

May 21, 2024, 8:05 AM EDT - 1 year ago

Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease

May 14, 2024, 11:00 AM EDT - 1 year ago

Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)

May 8, 2024, 8:00 PM EDT - 1 year ago

Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering

Apr 15, 2024, 8:28 AM EDT - 1 year ago

Organovo's fatty liver disease drug meets main goal in mid-stage study

Apr 15, 2024, 8:05 AM EDT - 1 year ago

Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo

Jan 25, 2024, 8:05 AM EST - 1 year ago

Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn's and Colitis Congress

Jan 9, 2024, 8:05 AM EST - 1 year ago

Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn's and Colitis Congress

Dec 6, 2023, 8:05 AM EST - 1 year ago

Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results

Nov 13, 2023, 8:05 AM EST - 1 year ago

CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan

Nov 8, 2023, 8:05 AM EST - 1 year ago

Organovo Highlights FXR314 Combination Therapy Potential and Plan

Sep 8, 2023, 12:46 PM EDT - 1 year ago

Organovo to Participate in the H.C. Wainwright Global Investment Conference

Aug 23, 2023, 8:05 AM EDT - 1 year ago

Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data

Mar 21, 2023, 8:05 AM EDT - 2 years ago

Organovo Announces FXR Program

Nov 15, 2022, 8:05 AM EST - 2 years ago

Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn's Disease Drug Candidates

Sep 6, 2022, 8:20 AM EDT - 2 years ago

Organovo to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Sep 6, 2022, 8:05 AM EDT - 2 years ago

Organovo Announces Postponement of Annual Meeting of Stockholders

May 17, 2022, 8:05 AM EDT - 3 years ago

Organovo Achieves 3D Tissue Model for Crohn's Disease

Mar 1, 2022, 8:05 AM EST - 3 years ago

UPDATE -- Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents

Feb 23, 2022, 8:05 AM EST - 3 years ago

Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents

Feb 18, 2022, 4:00 PM EST - 3 years ago

Organovo Holdings, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Feb 18, 2022, 1:00 PM EST - 3 years ago

Organovo Welcomes New Sr. Vice President of Strategy and Business Development

Feb 2, 2022, 12:00 PM EST - 3 years ago

Organovo Guides on Patent Portfolio and Successful IPR Defense of Two Patents

Jan 10, 2022, 12:00 PM EST - 3 years ago

Organovo Files Counterclaims In Patent Lawsuit Brought Against It by CellInk

Nov 30, 2021, 8:05 AM EST - 3 years ago

Organovo On Track to Establish Human 3D Disease Model in Inflammatory Bowel Disease in 2022

Sep 17, 2021, 4:10 PM EDT - 3 years ago

Organovo Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum

May 28, 2021, 9:54 AM EDT - 4 years ago

Organovo: New Strategy Targeting Internal Pipeline Development With Customized 3D Human Tissues Offers Upside

Mar 11, 2021, 3:58 PM EST - 4 years ago

Catherine Wood's ARK Investment Slashes Organovo Holding

Mar 2, 2021, 8:05 AM EST - 4 years ago

Organovo Announces Participation at the H.C. Wainwright Global Life Sciences Conference March 9-10 2021 (VIRTUAL CONFERENCE)

Sep 3, 2020, 4:05 PM EDT - 5 years ago

Organovo Regains Compliance with Nasdaq Minimum Bid Price Requirement

Aug 17, 2020, 8:05 AM EDT - 5 years ago

Organovo Announces One-for-Twenty Reverse Stock Split

Oct 2, 2019, 7:31 PM EDT - 6 years ago

Organovo Acknowledges Receipt of Proposal

May 23, 2019, 5:05 PM EDT - 6 years ago

Organovo Holdings, Inc. (ONVO) CEO Taylor Crouch on Q4 2019 Results - Earnings Call Transcript